Data / Drug companies / Medline Industries, LP
Medline Industries, LP: 115 products in the FDA NDC directory, labeler code 53329
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Medline Industries, LP (labeler code 53329) lists 115 products in the FDA National Drug Code Directory, covering 44 finished drugs by generic name. By type: 114 over the counter drugs, 1 prescription drugs. Its main marketing category is over the counter monograph drugs. The newest product started marketing on August 28, 2026.
The request: Watch Medline Industries, LP (FDA labeler code 53329): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 53329
- Products in commercial distribution
- 115
- Packages
- 235
- Finished drugs by generic name
- 44
- Prescription products
- 1
- Over the counter products
- 114
- Flagged as original packager
- 103 of 103 products that carry the flag
- Started marketing in the last 12 months
- 17
- Products with a marketing end date set
- 19
- Earliest marketing start
- April 30, 2002
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Over the counter monograph drugs | 103 | 89.6% |
| Generic drugs (ANDA) | 10 | 8.7% |
| New drug applications (NDA) | 2 | 1.7% |
Products by type
| Type | Products | Share |
|---|---|---|
| Over the counter drugs | 114 | 99.1% |
| Prescription drugs | 1 | 0.9% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Swab | 15 | 13% |
| Cloth | 12 | 10.4% |
| Cream | 11 | 9.6% |
| Ointment | 9 | 7.8% |
| Solution | 8 | 7% |
| Tablet | 7 | 6.1% |
| Liquid | 7 | 6.1% |
| Gel | 7 | 6.1% |
| Spray | 6 | 5.2% |
| Paste | 6 | 5.2% |
| Patch | 5 | 4.3% |
| Tablet, coated | 2 | 1.7% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Medline | 53329-605 | Tablet | Over the counter monograph drugs | August 28, 2026 |
| Medline | 53329-603 | Tablet, film coated | Generic drugs (ANDA) | August 28, 2026 |
| Medline | 53329-221 | Tablet, extended release | Generic drugs (ANDA) | August 28, 2026 |
| Medline | 53329-199 | Tablet | Over the counter monograph drugs | August 28, 2026 |
| Medline Industries | 53329-036 | Tablet, film coated | Generic drugs (ANDA) | August 28, 2026 |
| Medline | 53329-256 | Ointment | Over the counter monograph drugs | August 5, 2026 |
| Medline | 53329-604 | Tablet | Over the counter monograph drugs | July 20, 2026 |
| Medline | 53329-271 | Cream | Over the counter monograph drugs | July 1, 2026 |
| Medline | 53329-600 | Tablet, delayed release | Over the counter monograph drugs | June 29, 2026 |
| Medline | 53329-257 | Ointment | Over the counter monograph drugs | June 24, 2026 |
| Medline | 53329-255 | Paste | Over the counter monograph drugs | June 15, 2026 |
| Medline | 53329-251 | Lotion | Over the counter monograph drugs | June 9, 2026 |
| Medline | 53329-259 | Cream | Over the counter monograph drugs | June 8, 2026 |
| Medline | 53329-234 | Swab | Over the counter monograph drugs | April 16, 2026 |
| Medline | 53329-230 | Gel | Over the counter monograph drugs | April 8, 2026 |
| Medline | 53329-232 | Swab | Over the counter monograph drugs | March 30, 2026 |
| Medline | 53329-233 | Swab | Over the counter monograph drugs | March 25, 2026 |
| Medline | 53329-149 | Cream | Over the counter monograph drugs | June 1, 2025 |
| Medline | 53329-973 | Patch | Over the counter monograph drugs | February 1, 2025 |
| Medline | 53329-972 | Patch | Over the counter monograph drugs | February 1, 2025 |
| Medline | 53329-218 | Cream | Over the counter monograph drugs | October 1, 2024 |
| Medline | 53329-125 | Swab | Over the counter monograph drugs | September 1, 2024 |
| Medline | 53329-189 | Ointment | Over the counter monograph drugs | August 1, 2024 |
| Medline | 53329-194 | Tablet | Over the counter monograph drugs | July 1, 2024 |
| Medline | 53329-121 | Swab | Over the counter monograph drugs | July 1, 2024 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.